Page results
-
This page has been written by the Physiotherapy Services at the Royal London Hospital for Integrated Medicine. It is for patients who have been referred to the clinic.
-
This page, written by the Physiotherapy Services at the Royal London Hospital for Integrated Medicine, is intended for patients (or their family or carers) who have been referred to the clinic.
-
Dr Zandi is a consultant neurologist. He works on central and peripheral nervous system neuroimmunological diseases, particularly autoimmune encephalitis (eg. associated with NMDAR, LGI1 or related autoantibodies, COVID-19 neurology), with a broader research interest in all central and peripheral neuroimmunology, CNS vasculitis and amyloid related angiopathy, neurological involvement in systemic lupus erythematosus and related rheumatological conditions.
-
Leila Hail and Gema Martinez-Garcia have been announced as finalists for the 2021 Royal College of Nursing (RCN) Awards in the Outstanding Contribution to Infection Prevention and Control category.
-
At UCLH we use many different drugs to treat patients with cancer. Chemotherapy is the treatment of cancer with drugs designed to control or destroy the growth of the tumour.
-
UCLH continues to achieve excellent results in the National Inpatient Survey. In 2021 patients rated their overall care as 8.5 out of 10 which is the top score in London and the second best in the Shelford Group.
-
C. diff is a bacterium (a “bug”) that lives harmlessly in the bowel (gut) of approximately three per cent of people. If the balance of C. diff and good bacteria is disrupted (for example when taking antibiotics), the good bacteria may be killed and C. diff can multiply and produce toxins. These toxins cause inflammation in the bowel and diarrhoea.
-
Information and contact details for our arts team and UCLH archivist.
-
This page explains what a low-phosphate diet is. It also provides information about foods you can eat and foods to avoid when taking a medicine called futibatinib.
-
UCLH has recruited the first participant in Europe to a global clinical trial for adults with Myotonic Dystrophy Type 1 (DM1)- a genetic condition and type of muscular dystrophy that causes progressive muscle weakness and wasting.
File results
-
FOI/2023/0072 - Contact centre
-
FOI/2023/0073 - Telephony and UC/ collaboration, Microsoft 365 licence and on-premise or cloud storage
-
FOI/2023/0078 - Total loss written off in 2021/22
-
FOI/2023/0088 - Appointments changed from in person to telephone due to industrial action
-
FOI/2021/0284 - Sleep respiratory service
-
FOI/2023/0099 - Number of autoclaves used at Trust
-
FOI/2023/0101 - Trauma protocols in pregnant patients
-
FOI/2023/0103 - Genetic Haemochromatosis patients
-
FOI/2023/0117 - EPRR Team contact information
-
FOI/2023/0125 - Staffing rota/ planning to support working parents